Novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases

Nuvig Therapeutics is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases, with a particular emphasis on their lead investigational drug candidate, NVG-2089. This novel immunomodulator is designed to target type II Fc receptors, triggering endogenous regulatory mechanisms that help reduce autoimmune dysregulation without the immunosuppressive effects commonly associated with existing therapies. NVG-2089 has shown promising anti-inflammatory effects in preclinical studies, particularly in models characterized by activated B cells, T cells, and myeloid immune cells. The drug has received fast track designation from the FDA for its development in treating bullous pemphigoid, and its clinical development is currently underway.

The underlying science of Nuvig's approach revolves around the modulation of immune function through the manipulation of antibody sialylation. In autoimmune patients, low levels of sialylation lead to heightened pro-inflammatory responses. Nuvig's technology aims to mimic the effects of sialylated immunoglobulin G (IgG) antibodies, which can bind to type II Fcγ receptors and restore an anti-inflammatory state. Their proprietary platform, referred to as BESTech™ (Biologic Enhancement of Self Tolerance), combines engineered Fc fragments with full-length antibodies to enhance therapeutic efficacy. This innovative approach seeks to provide a safer and more effective alternative to traditional immunosuppressive therapies, ultimately improving the quality of life for patients suffering from autoimmune conditions.

United States

Nuvig Therapeutics is a science-driven research and clinical development organization focused on translating novel scientific insights into therapies for patients with chronic autoimmune and inflammatory diseases.

Nuvig Therapeutics

Company Details